N'- (2- chloroethyl)- N- (2- (methylsulfonyl)ethyl)- N'- nitrosourea

05/15/2002 - "Cystemustine cured the tumor-bearing mice with 100% efficacy. "
05/01/2002 - "Pharmacokinetic study of cystemustine, administered on a weekly schedule in cancer patients."
11/27/1996 - "Cystemustine is a new nitrosourea with high anti-tumor activity and a short plasma half-life in mice. "
12/01/1994 - "Preliminary pharmacological assays were carried out in nude mice bearing the M4Beu tumor to determine whether the BNAG-cystemustine combination has greater antitumor activity than cystemustine alone. "
10/01/2005 - "In a phase II trial, we evaluated the anti-tumor effects of cystemustine chemotherapy, a new nitrosourea, as a second-line treatment. "

08/01/2006 - "In this study, we have assessed the efficacy of a nitrosourea, cystemustine, in treating patients with recurrent high grade glioma with overall survival analysis as primary end-point. "
08/01/2006 - "In conclusion, cystemustine has encouraging activity for patients with recurrent high grade glioma."
08/01/2006 - "Multivariate analysis showed that WHO performance status, histology and response to cystemustine were significant prognostic factors for survival of patients with recurrent glioma. "
08/01/2006 - "Cystemustine in recurrent high grade glioma."
09/01/2000 - "In conclusion, cystemustine at 60 mg/m2 has moderate clinical activity in relapsing glioma. "

05/15/2002 - "The effects of the nitrosourea cystemustine were investigated in skeletal muscles from both healthy and colon 26 adenocarcinoma-bearing mice, an appropriate model for testing the impact of cytostatic agents. "
07/01/2001 - "Cancer cachexia was induced using colon 26 adenocarcinoma, which is characteristic of the human condition, and can be cured with 100% efficacy using an experimental nitrosourea, cystemustine (C(6)H(12)CIN(3)O(4)S). "
09/01/2000 - "Cancer cachexia was induced in mice with colon 26 adenocarcinoma, which is a small and slow-growing tumor characteristic of the human condition, and can be cured with 100% efficacy using an experimental nitrosourea, cystemustine (C6H12ClN3O4S). "

09/01/2000 - "injection of cystemustine (20 mg/kg) 3 days after the onset of cachexia. "
07/01/2001 - "Three days after cachexia began, healthy and tumor-bearing mice were given a single intraperitoneal injection of cystemustine (20 mg/kg). "
07/01/2001 - "Cancer cachexia was induced using colon 26 adenocarcinoma, which is characteristic of the human condition, and can be cured with 100% efficacy using an experimental nitrosourea, cystemustine (C(6)H(12)CIN(3)O(4)S). "
09/01/2000 - "Cancer cachexia was induced in mice with colon 26 adenocarcinoma, which is a small and slow-growing tumor characteristic of the human condition, and can be cured with 100% efficacy using an experimental nitrosourea, cystemustine (C6H12ClN3O4S). "
09/01/2000 - "In contrast, mucosal damage and a 17% reduction in small intestinal protein mass (P < 0.05) were evident in healthy mice treated with cystemustine, suggesting that the effects of chemotherapy on the small intestine in a state of cancer cachexia are not additive, which was an unexpected finding. "

12/01/1999 - "From May 1991 to January 1996, 54 patients with advanced malignant melanoma were enrolled into a phase II trial testing the new nitrosourea cystemustine, administrated intravenously as a 15 min infusion every 2 weeks at 90 mg/m2 for three cycles followed by 60 mg/m2. "
12/01/1999 - "Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group."
01/01/1996 - "Results of a phase II trial with cystemustine in advanced malignant melanoma. "
01/01/2019 - "Twenty-two patients (20 with metastatic melanoma and 2 with recurrent gloma) received a median of four cycles of the combination of a 1-day MR diet with cystemustine (60 mg/m2) every 2 weeks. "
12/01/2009 - "Twenty-two patients (20 with metastatic melanoma and 2 with recurrent gloma) received a median of 4 cycles of the association of a 1-day MET-free diet with cystemustine (60 mg/m(2)) every two weeks. "